-+ 0.00%
-+ 0.00%
-+ 0.00%

Syndax reports 88% response rate in SAVE trial of Revuforj combo for relapsed/refractory AML

PUBT·06/11/2026 11:01:59
Listen to the news
Syndax reports 88% response rate in SAVE trial of Revuforj combo for relapsed/refractory AML
  • Syndax reported Journal of Clinical Oncology publication of Phase 1/2 SAVE results, presented simultaneously at the EHA 2026 Congress.
  • An all-oral Revuforj regimen produced broad, deep remissions in heavily pretreated relapsed or refractory AML, including patients previously treated with venetoclax.
  • A large share of responders advanced to stem cell transplant, supporting the regimen’s potential as a bridge to curative-intent therapy.
  • Safety looked manageable for combination use, with no new signals highlighted in the report.
  • Data underpin further combination development, including the pivotal EVOLVE-2 study in newly diagnosed patients unfit for intensive chemotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110700PRIMZONEFULLFEED9745488) on June 11, 2026, and is solely responsible for the information contained therein.